TD Asset Management Reduces Stake in Amphastar Pharmaceuticals

Institutional investor sells over 100,000 shares of the generic drug maker

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

TD Asset Management Inc., a major institutional investor, decreased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 5.1% in the third quarter, according to a recent SEC filing. The firm now owns 1,931,892 shares of the company's stock, valued at $51.5 million, after selling 103,038 shares.

Why it matters

Amphastar Pharmaceuticals is a key player in the generic drug market, producing injectable and inhalation products for hospitals, emergency medical services, and retail pharmacies. Changes in ownership by major institutional investors can signal shifts in market sentiment and impact the company's stock price and future growth prospects.

The details

According to the 13F filing, TD Asset Management sold 103,038 shares of Amphastar Pharmaceuticals during the third quarter, reducing its stake in the company to 4.16%. The firm remains a significant shareholder, owning nearly 2 million shares worth over $51 million. Several other hedge funds have also adjusted their positions in Amphastar in recent quarters, with some increasing and others decreasing their holdings.

  • TD Asset Management filed its 13F report for the third quarter on February 27, 2026.

The players

TD Asset Management Inc.

A major institutional investor and asset management firm that owns a significant stake in Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals, Inc.

A specialty pharmaceutical company that develops, manufactures, and commercializes injectable and inhalation products, including generic drugs such as epinephrine, naloxone, and lidocaine.

Got photos? Submit your photos here. ›

The takeaway

The reduction in TD Asset Management's position in Amphastar Pharmaceuticals reflects the ongoing shifts in institutional ownership of the generic drug maker. While the firm remains a major shareholder, this move could signal broader market trends and the need for Amphastar to continue diversifying its product portfolio and customer base to maintain growth.